Your browser doesn't support javascript.
loading
Specific Cytotoxicity of Targeted 177Lu and 212Pb-Based Radiopharmaceuticals.
Pankratov, A A; Nemtsova, E R; Plyutinskaya, A D; Vorontsova, M S; Chuvilin, D Yu; Egorova, B V; Kokov, K V; Deev, S M; Lebedenko, E N; Proshkina, G M; Shul'ga, A A; Golovachenko, V A; Shegai, P V; Kaprin, A D.
Afiliação
  • Pankratov AA; P. A. Hertsen Moscow Oncology Research Institute - Affiliated Branch of National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, Moscow, Russia.
  • Nemtsova ER; P. A. Hertsen Moscow Oncology Research Institute - Affiliated Branch of National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, Moscow, Russia. nemtz@yandex.ru.
  • Plyutinskaya AD; P. A. Hertsen Moscow Oncology Research Institute - Affiliated Branch of National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, Moscow, Russia.
  • Vorontsova MS; P. A. Hertsen Moscow Oncology Research Institute - Affiliated Branch of National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, Moscow, Russia.
  • Chuvilin DY; National Research Center Kurchatov Institute, Moscow, Russia.
  • Egorova BV; National Research Center Kurchatov Institute, Moscow, Russia.
  • Kokov KV; National Research Center Kurchatov Institute, Moscow, Russia.
  • Deev SM; M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
  • Lebedenko EN; Research School of Chemistry and Applied Biomedical Sciences, National Research Tomsk Polytechnic University, Tomsk, Russia.
  • Proshkina GM; M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
  • Shul'ga AA; Research School of Chemistry and Applied Biomedical Sciences, National Research Tomsk Polytechnic University, Tomsk, Russia.
  • Golovachenko VA; M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
  • Shegai PV; M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
  • Kaprin AD; Research School of Chemistry and Applied Biomedical Sciences, National Research Tomsk Polytechnic University, Tomsk, Russia.
Bull Exp Biol Med ; 171(5): 627-632, 2021 Sep.
Article em En | MEDLINE | ID: mdl-34626281
ABSTRACT
Two radiopharmaceutical preparations were developed on the basis of artificial targeted polypeptide ZHER2 specific to HER2/neu tumor marker and radionuclides 177Lu (ZHER2-HSA-chelator-177Lu) or 212Pb (ZHER2-HSA-chelator-212Pb). The objective was to evaluate in vitro the cytotoxic activity of the targeted radiopharmaceuticals using two cultured human breast cancer cell lines with different expression of HER2/neu SK-BR3 (high expression of HER2/neu) and MCF-7 (low expression of HER2/neu). It was shown that the cytotoxic effect of both preparations was significantly higher against the SK-BR-3 cells. The cytotoxicity correlated with the incubation period (it was higher after 72 h than after 24 h) and was significantly more pronounced in comparison with activity of radionuclide salts without a specific ligand. In vivo preclinical study of these pharmaceuticals seems to be very promising in animals with xenografted tumors showing high expression of HER2/neu marker.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Radioisótopos / Neoplasias da Mama / Radioisótopos de Chumbo / Imunotoxinas / Lutécio / Antineoplásicos Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Federação Russa

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Radioisótopos / Neoplasias da Mama / Radioisótopos de Chumbo / Imunotoxinas / Lutécio / Antineoplásicos Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Federação Russa